Zeo ScientifiX (ZEOX) Capital Expenditures (2017 - 2026)

Zeo ScientifiX (ZEOX) posted quarterly Capital Expenditures of $64000.0 for Q2 2026, up 357.14% quarter-over-quarter from $14000.0 in Q1 2026.

Zeo ScientifiX (ZEOX) Capital Expenditures (2017 - 2026) Analysis & Trends

Zeo ScientifiX's Capital Expenditures history runs 8 years deep, the most recent figure standing at $64000.0 for Q2 2026.

In Q2 2026, Capital Expenditures changed N/A year-over-year to $64000.0; the TTM figure through Apr 2026 stood at $84000.0 (changed N/A YoY), while the FY2025 annual figure was $23000.0, changed N/A from the prior year.
Capital Expenditures for Q2 2026 stood at $64000.0, up from $14000.0 in the prior quarter.
The five-year high for Capital Expenditures was $308224.0 in Q4 2022, with the low at $6000.0 in Q4 2023.
The 3-year median for Capital Expenditures is $97741.5 (2022), against an average of $115592.9.
The sharpest annual moves came in 2022 and 2023: Capital Expenditures soared 235.32% in 2022, then tumbled 98.05% in 2023.
Zeo ScientifiX's Capital Expenditures stood at $308224.0 in 2022, then tumbled by 98.05% to $6000.0 in 2023, then soared by 966.67% to $64000.0 in 2026.
Business Quant data shows ZEOX's Capital Expenditures at $64000.0 in Q2 2026, $14000.0 in Q1 2026, and $6000.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Zeo ScientifiX	10.51 Mn	8.67 Mn	2.06 Mn	64,000.00

Download Data